当前位置: X-MOL 学术Ophthalmic Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Optical Coherence Tomography Biomarkers - Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19 mg Fluocinolone Acetonide Implant
Ophthalmic Research ( IF 2.1 ) Pub Date : 2021-02-18 , DOI: 10.1159/000515306
Bernardete Pessoa 1, 2 , André Ferreira 1, 3 , João Leite 1 , João Figueira 4, 5 , Angelina Meireles 1, 2 , João Melo Beirão 1, 2
Affiliation  

Background: The 0.19 mg fluocinolone acetonide (FAc) implant (ILUVIEN®; Alimera Sciences Ltd, Hampshire, UK) was approved for the treatment of vision impairment associated with chronic and refractory diabetic macular edema (DME). Objectives: To quantitatively assess functional and structural features in non-vitrectomized and vitrectomized DME patients after being treated with a FAc implant Methods: Retrospective review of patients with DME receiving single intravitreal injection of the FAc implant. The study was designed to analyze the presence of quantitative structural OCT biomarkers at baseline and 12 months after FAc therapy according to vitreous status. Results: A total of 41 eyes from 30 patients were included in this study. At 12 months post-injection, vitrectomized patients had a lower central foveal thickness (CFT, p=0.017) and fewer hyperreflective dots (HRD, p=0.028) compared with non-vitrectomized. Thirty (73%) patients presented a significant functional improvement with 17 (42%) increasing at least 15 ETDRS letters. Overall, 22 (54%) eyes had a complete resolution of DME at 12 months visit. Patients who needed additional therapy had a higher prevalence of subretinal fluid (SRF, 42% vs 3% p=0.005) at baseline. Conclusions: This study supports the effectiveness of the FAc implant and reports significant changes at 12 months post-FAc injection.


中文翻译:

光学相干断层扫描生物标志物 - 玻璃体状态对 0.19 mg 醋酸氟轻松植入物治疗糖尿病性黄斑水肿结果的影响

背景:0.19 mg 醋酸氟轻松 (FAc) 植入物 (ILUVIEN®; Alimera Sciences Ltd, Hampshire, UK) 被批准用于治疗与慢性和难治性糖尿病黄斑水肿 (DME) 相关的视力障碍。目的:定量评估非玻璃体切除和玻璃体切除的 DME 患者在接受 FAc 植入物治疗后的功能和结构特征 方法:对接受单次玻璃体内注射 FAc 植入物的 DME 患者进行回顾性审查。该研究旨在根据玻璃体状态分析基线和 FAc 治疗后 12 个月定量结构 OCT 生物标志物的存在。结果:本研究共纳入 30 名患者的 41 只眼。注射后 12 个月,玻璃体切除患者的中央凹厚度较低(CFT,p=0. 017)和更少的高反射点(HRD,p = 0.028)与非玻璃体切除术相比。30 名 (73%) 患者出现显着的功能改善,其中 17 名 (42%) 增加了至少 15 个 ETDRS 字母。总体而言,22 只(54%)眼在 12 个月就诊时 DME 完全消退。需要额外治疗的患者在基线时视网膜下液的患病率较高(SRF,42% vs 3% p=0.005)。结论:本研究支持 FAc 植入物的有效性,并报告了 FAc 注射后 12 个月的显着变化。需要额外治疗的患者在基线时视网膜下液的患病率较高(SRF,42% vs 3% p=0.005)。结论:本研究支持 FAc 植入物的有效性,并报告了 FAc 注射后 12 个月的显着变化。需要额外治疗的患者在基线时视网膜下液的患病率较高(SRF,42% vs 3% p=0.005)。结论:本研究支持 FAc 植入物的有效性,并报告了 FAc 注射后 12 个月的显着变化。
更新日期:2021-02-18
down
wechat
bug